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Abstract
Immunoglobulin G (IgG) replacement therapy is a standard treatment for patients with primary immunodeficiency diseases
(PIDs). Hizentra®, a 20% human subcutaneous IgG (SCIG), is approved for biweekly administration for PIDs. The aim of the
multicenter IBIS study was to prospectively investigate the efficacy of biweekly Hizentra® compared with previous IVIG or
SCIG treatment regimens in patients with PIDs. The study consisted of a 12-month retrospective period followed by 12-month
prospective observational period. The main endpoints included pre-infusion IgG concentrations, proportion of patients with
serious bacterial infections (SBIs), other infections, hospitalizations due to PID-related illnesses, and days with antibiotics during
the study periods. Of the 36 patients enrolled in the study, 35 patients continued the study (mean age 26.1 ± 14.4 years; 68.6%
male). The mean pre-infusion IgG levels for prior immunoglobulin regimens during the retrospective period (7.84 ± 2.09 g/L)
and the prospective period (8.55 ± 1.76 g/L) did not show any significant variations (p = 0.4964). The mean annual rate of SBIs/
patient was 0.063 ± 0.246 for both prospective and retrospective periods. No hospitalizations related to PIDs were reported
during the prospective period versus one in the retrospective period. All patients were either very (76.5%) or quite (23.5%)
satisfied with biweekly Hizentra® at the end of the study. In conclusion, the IBIS study provided real-world evidence on the
efficacy of biweekly Hizentra® in patients with PIDs, thus verifying the data generated by the pharmacometric modeling and
simulation study in a normal clinical setting.
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Introduction
Primary immunodeficiency diseases (PIDs) are a heteroge-
neous group of chronic congenital disorders of the immune
system where the immune system is compromised due to
defects in one or more of its components [1]. The most com-
mon forms of PIDs with antibody deficiency (defined as pri-
mary antibody deficiency [PAD]) are common variable immu-
nodeficiency (CVID), X-linked agammaglobulinemia (XLA),
and autosomal recessive agammaglobulinemia (ARA) [2].
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PIDs are estimated to affect 6 million people worldwide, al-
though their exact prevalence remains unclear [3]. Patients
with PIDs are more prone to recurrent, prolonged, and/or
severe infections, and need timely diagnosis and treatment
[4, 5].
Replacement therapy with intravenous human polyvalent
IgG (IVIG) has been a gold standard treatment for patients
with PIDs, in whom increasing serum IgG levels provide pas-
sive immunity to fight recurrent infections, thus significantly
improving quality of life [6–8]. However, IVIG therapy is
associated with a high incidence of adverse reactions, partic-
ularly in children, and it is often difficult to identify an appro-
priate vein for administration of therapy [9, 10]. Moreover,
decreased efficacy with IVIG (the wear-off effect) towards
the end of 3–4-week dosing cycle has also been quantitatively
reported, which may be improved by increasing the IgG dose
or reducing the dosing interval and/or a switch to subcutane-
ous immunoglobulin (SCIG) [11]. These challenges with
IVIG therapy have led to the development of SCIG products,
which are currently used in the treatment of patients with
PIDs.
SCIG formulations infused weekly at lower IgG doses re-
sult in higher pre-infusion IgG values compared with monthly
IVIG administration [12, 13]. Additionally, SCIG has im-
proved patient compliance due to reduced adverse events
(AEs), decreased time required for each individual infusion
and ease of self-administration compared with IVIG
[13–16]. Although, like most subcutaneous injections,
SCIGs cause local reactions at the site of injection such as
redness, itching, and swelling, these AEs tend to decline over
time [17, 18].
Hizentra® (20% human SCIG, CSL Behring AG) is a
SCIG formulation approved by the US Food and Drug
Administration (FDA) and European Medical Agency for
the treatment of patients with PIDs [19, 20]. A pharmaco-
kinetic modeling and simulation study of Hizentra® in pri-
mary immunodeficiency predicted that biweekly adminis-
tration of Hizentra® offers a viable alternative to weekly
subcutaneous dosing, allowing more flexible and opti-
mized IgG regimens in patients with PIDs [21]. The results
of a retrospective record review of patients with PIDs treat-
ed with biweekly Hizentra® were consistent with the re-
sults of the pharmacokinetic modeling and simulation
study [22]. However, a prospective clinical study to con-
firm these findings and to study the effect of a change in
dosing regimen from weekly to biweekly on the frequency
and seriousness of infections in normal clinical practice
was warranted.
The Infusione Bimensile di Immunoglobuline Sottocute
(IBIS; i.e., biweekly infusion of SCIG) study is the first pro-
spective clinical study that aimed to compare the clinical and
laboratory parameters of patients with PIDs receiving biweek-
ly treatment with Hizentra® with their previous IgG-based
treatments. The study also aimed to describe the profile of
patients considered suitable for biweekly treatment with
Hizentra®.
Methods
Study Design
This multicenter, prospective, observational cohort study with
a retrospective analysis included patients with PIDs who
underwent treatment with biweekly Hizentra®. Clinical data
for each enrolled patient were collected for a 24-month obser-
vation period, which included 12months each of retrospective
and prospective observation (Fig. 1). The overall study dura-
tion was 18–6 months for enrolment of patients during which
retrospective data were collected for up to 12 months prior to
enrolment, followed by 12 months of prospective evaluation,
which included data collection at 3, 6, and 12 months after
enrolment using electronic case report forms. Enrolment in the
study and treatment with Hizentra® were based on the judg-
ment of the patients’ physician with the guarantee that the
therapeutic choice was made in accordance with normal clin-
ical practice.
Patients who met the following criteria were included in
t h e s t udy : p a t i e n t s ( 1–70 yea r s o f age ) w i t h
hypogammaglobulinemia due to PIDs who required IgG re-
placement therapy at a dose that the investigator considered
stable and protective against most infections, patients under-
going treatment with IgG (IVIG or SCIG) for at least
12 months and who had switched to Hizentra® at least
3 months before enrolment and who changed the frequency
of administration of SCIG fromweekly to biweekly (i.e., once
every 2 weeks) upon enrolment, and patients for whom the
minimum retrospective data were available for the 12 months
preceding enrolment. Minimum retrospective data included at
least one measurement of minimum plasma IgG concentration
representative of the mean value during the period, data on
previous IgG therapy (SCIG/IVIG, monthly doses, frequency
of infusions, number of infusion sites for each session, infu-
sion speed, number of pumps used (only for SCIG); number
and type of serious bacterial (pneumonia, bacteremia/septice-
mia, osteomyelitis/septic arthritis, meningitis, visceral ab-
scess) and other infections, and number of hospitalizations
for PID-related illness. Exclusion criteria were any of the fol-
lowing: treatment with IVIG-type IgG therapy within
3 months prior to the enrolment visit; protein-losing illnesses;
solid or onco-hematological neoplasms; concomitant treat-
ment with high-dose systemic corticosteroids, immunosup-
pressive drugs, or plasma or other blood derivatives; positive
viraemia for HIV-1, HIV-2, hepatitis C, or positive hepatitis B
markers; pregnancy; and participation in clinical trials on in-
vestigational active ingredient or any other medicinal product
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that could interfere with the IgG replacement therapy.
Concomitant or prior therapies for comorbidities related to
PID or other pathologies were allowed during the study
period.
The study was approved by the Comitato Etico Area Vasta
Centro; Azienda Ospedaliera Universitaria Careggi, Firenze;
and the Ethics Committees of each study center and was con-
ducted in accordance with the Declaration of Helsinki and the
current regulations for observational studies. All patients com-
pleted an informed consent form before participation in the
study.
Endpoints
The primary study endpoints included pre-infusion serum
IgG concentrations for the retrospective and prospective
periods; IgG concentration 7 days after subcutaneous injec-
tion of Hizentra® for the first three administrations during
the prospective period; proportion of patients with serious
bacterial (bacterial pneumonia, bacteremia/septicemia,
osteomyelitis/septic arthritis, bacterial meningitis, visceral
abscess, as defined by the US FDA [23]) and other infec-
tions and the number and types of infections, for both ret-
rospective and prospective periods; and proportion of pa-
tients with hospitalizations due to illnesses related to PID,
as well as the total number of hospitalizations during the
retrospective and prospective periods. Secondary endpoints
included determination of baseline characteristics of pa-
tients enrolled in the study (age, sex, weight, severity of
PID) and manual ability of administration of Hizentra®
during the retrospective period.
Clinical analyses of IgG levels were carried out in the lab-
oratories of each center involved in the study; a central labo-
ratory was not used for the prospective study testing.
Overall satisfaction with biweekly Hizentra® was evaluat-
ed by the patients’ physician during the follow-up visits.
Patient satisfaction of biweekly Hizentra® treatment was
assessed as follows: very satisfied, quite satisfied, little satis-
fied, and not satisfied.
Statistical Analysis
The sample size for the study was determined based on feasi-
bility criteria. Based on the number of patients with PIDs
managed at the centers participating in this study, it was con-
sidered reasonable to include 30 patients (five patients/center
on an average), and assuming 10% non-evaluable patients, it
was expected to have 27 patients for the primary analyses.
Precision of the estimates was evaluated in terms of confi-
dence intervals (CIs) for mean IgG concentrations and the
proportion of patients with infections based on reports of pre-
vious studies with Hizentra® [13, 14].
Statistical analyses for primary endpoints included
evaluable patients for whom IgG plasma levels, infections,
and hospitalizations for at least two of the three follow-up
periods were available, while the secondary endpoints were
evaluated in all enrolled patients who met the inclusion
criteria. For primary objectives, the 95% CI limits were pre-
dicted for both observation periods. The 95% CI for the mean
IgG concentration was expected to have a half-width of 0.5 g/
L (expected mean ± standard deviation [SD] 8.10 ± 1.34 g/L),
while the 95% CI for the proportions of patients with infec-
tions were expected to have a half-width of 18.5% (if the
expected proportion was 60%) or 12.3% (if the expected pro-
portion was 88%). Appropriate non-parametric statistical tests
were used, wherever applicable, to determine the statistically
significant changes (p = 0.05) between the two observation
periods.
Results
Patient Disposition and Baseline Characteristics
A total of 36 patients were enrolled at seven centers in Italy, of
which 35 patients (97.2%) continued the study. One patient
withdrew informed consent the day after enrolment before
starting the biweekly regimen, as they were no longer willing
to participate in the study. All 35 patients had data available
for analysis of IgG therapy prior to enrolment, infusion
Fig. 1 Study design. IVIG
intravenous immunoglobulin,
SCIG subcutaneous
immunoglobulin, T time
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parameters during the biweekly Hizentra® administration and
safety; 23 patients (63.9%) were considered evaluable for the
primary analysis of IgG levels during the prospective period
and 32 patients (88.9%) were evaluable for the primary anal-
ysis of infections/hospitalizations during the prospective peri-
od. Patients evaluable for primary analysis of IgG levels and
infections/hospitalizations during the prospective period in-
cluded all patients for whom data on pre-infusion IgG concen-
trations and infections/hospitalizations was available for at
least two of the three follow-up visits at 3, 6, and 12 months
after enrolment.
Of the 36 enrolled patients, 34 patients (94.4%) completed
the study at the end of the prospective period, and two patients
were terminated due to withdrawal of informed consent.
Reasons for withdrawal of informed consent included no lon-
ger willing to participate in the study, and return to weekly
regimen of Hizentra® after an AE which was not considered
to be related to Hizentra®, reported by one patient each.
Mean ± SD age of the 35 patients who started the biweekly
regimen of Hizentra® was 26.1 ± 14.4 years (age range 2–
56 years; 25% of patients aged ≤ 14 years, 25% 14–24 years,
and 50% ≥ 24 years), of which 24were male (68.6%; Table 1).
The mean ± SD disease duration at enrolment was 10.2 ±
8.9 years (range 1–40 years): 25% of patients reported PID
for ≤ 4 years, 25% for 4–7 years, and 50% for ≥ 14 years
(Table 1). CVID was the most prevalent type of PID (n = 20,
57.1%) followed by XLA (n = 9, 25.7%; Table 1).
Fourteen patients reported at least one comorbidity related
to PID or other relevant ongoing pathologies at enrolment, of
which 8.6% of patients reported autoimmune disease and
34.3% reported other pathologies (the most frequent being
chronic sinusitis [five cases] and bronchiectasis [three cases];
Table 1).
IgG Therapy During the Retrospective Period
For the 36 patients enrolled in the study, the median duration
of IgG therapy (IVIG and/or SCIG) was 6.0 years (interquar-
tile range [IQR] 4.0–12.0). Twenty-three patients (65.7%)
were self-administering IgG therapy, and 13 patients required
assistance for administration of therapy from a relative.
The median duration of weekly treatment with Hizentra®
was 2.4 years (IQR 1.2–3.2); 77.1% of patients (n = 27) were
administered Hizentra® every 7 days, 17.1% (n = 6) every
10 days, and 5.7% (n = 2) every 6 days. At enrolment, 20%
of patients (n= 7) had received IVIG therapy every 3–4weeks,
the median exposure duration of which was 5.7 years (IQR
0.1–17.5).
The main reported reasons for switching from weekly in
the retrospective period to a biweekly Hizentra® regimen dur-
ing the study were better compatibility with personal needs
(n = 22, 62.9%), easily controllable disease (n = 13, 37.1%),
low body weight of patients (n = 9, 25.7%), and pediatric
patients (n = 8, 22.7%).
Pre-Infusion IgG Concentrations
A total of 23 patients were evaluable for pre-infusion IgG
concentrations at the end of the study. The median (IQR)
pre-infusion serum IgG concentration during the retrospective
period was 8.03 (7.10–9.25) g/L (n = 23). Median (IQR) pre-
infusion IgG concentrations during the prospective observa-
tion period at 3, 6, and 12 months after administration of
biweekly Hizentra® were 8.57 (8.05–9.79) g/L (n = 17),
8.15 (7.64–9.45) g/L (n = 21), and 7.98 (7.07–9.69) g/L
(n = 21), respectively (Table 2).
Median (IQR) intra-patient variation in pre-infusion IgG
concentrations between the retrospective and prospective
IgG values was 0.10 (− 0.82 to 1.22) g/L. No significant var-
iations in mean ± SD pre-infusion IgG levels between prior
regimens (7.84 ± 2.09) and biweekly Hizentra® (8.55 ±
1.76) were found (p = 0.4964, signed rank test).
During the retrospective period, treatment with Hizentra®
was administered with a median (IQR) dose per infusion of 6
(4–8; mean ± SD 5.9 ± 3.1 g) g, median duration of each infu-
sion was 1 (0.8–1.7) h, and median infusion speed for each
session was 20 (12.5–22.5) mL/h. Two infusion sites were
used during each session for 33 patients (94.3%), whereas a
unique infusion site was used for 2 patients (5.7%).
The median (IQR) duration of exposure to biweekly
Hizentra® was 12 (11.8–12.5) months, median dose per infu-
sion session was 10 (8–12; mean ± SD 9.8 ± 3.6 g) g, median
Table 1 Baseline characteristics of patients included in the study
Characteristic Evaluable patients, n = 35
Gender, n (%)
Male 24 (68.6)
Female 11 (31.4)
Age at enrolment, years 26.1 ± 14.4
BMI, kg/m2 23.1 ± 4.7
PID type at enrolment, n (%)
CVID 20 (57.1)
XLA 9 (25.7)
ARA 1 (2.9)
Othera 5 (14.3)
Disease duration at enrolment, years 10.2 ± 8.9
Comorbidities at enrolment, n (%)
Autoimmune disease 3 (8.6)
Other PID-related pathologies 12 (34.3)
Values are presented as mean ± standard deviation unless otherwise stated
ARA autosomal recessive agammaglobulinemia, BMI body mass index,
CVID common variable immunodeficiency, PID primary immunodefi-
ciency, SD standard deviation, XLA X-linked agammaglobulinemia
a IgG subclass deficiency (n = 4) and DiGeorge syndrome (n = 1)
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duration of each infusion was 1.6 (1.3–2.0) h, and median
infusion speed for each session was 25 (18–36) mL/h. Two
infusion sites were used during each session for 25 patients
(71.4%), three infusion sites were used for 6 patients (17.1%),
and four infusion sites were used for 3 patients (8.6%); only 1
patient (2.9%) used a single infusion site.
The slight reduction in the monthly dose of Hizentra®
observed during the prospective phase (median dose of 10 g/
infusion every 2 weeks) compared with the retrospective pe-
riod (median dose of 6 g/infusion every week) was due to
simplicity in the administration of the drug; in many cases, a
10-g (50 mL) vial of Hizentra® was used every 2 weeks.
Bacterial and Other Infections
Among the 32 patients evaluable for infections (patients with
available data on infections for at least two follow-up visits
who did not interrupt biweekly therapy with Hizentra®), two
patients (6.3%) reported a serious bacterial infection (SBI;
visceral abscess and bacterial pneumonia) during the prospec-
tive period, and bacterial pneumonia was reported by two
patients (6.3%) during the retrospective period. The mean
(± SD) annual rate of SBIs/patient during the prospective
and retrospective periods was identical (0.063 ± 0.246) and
was calculated taking into account an episode of pneumonia
which occurred in the prospective period but was erroneously
reported elsewhere in the database and was assessed as an SBI
after database lock.
At least one non-serious bacterial and non-bacterial infec-
tion (other infections) was reported in 24 patients (75%; 95%
CI 56.60, 88.54) each during the retrospective and prospective
observation period, and the total number of other infections
reported during the prospective and retrospective period were
62 and 40, respectively (Table 3). The most prevalent infec-
tions during the prospective study period were pharyngitis (14
cases), sinusitis (10 cases), and bronchitis (8 cases), and dur-
ing the retrospective period, these were pharyngitis (8 cases)
and bronchitis (12 cases).
Themedian (IQR) annual rate of other infections during the
retrospective and prospective observation period was 1.000
(0.50–2.00) and 1.767 (0.448–2.974). Median increase in the
annual rate of other infections during the prospective period
was not statistically significant (0.047; p = 0.0632, signed
rank test).
Antibiotic therapy for bacterial infections (serious and non-
serious) was reported by 60% of patients (n = 21) during the
retrospective period and 62.9% (n = 22) during the prospec-
tive period. Median (IQR) duration of antibiotic therapy for
serious and non-serious infections was 6 (0–20) days (n = 35)
during the retrospective period, and 7 (0–16) days during the
prospective period (n = 34).
Number of Hospitalizations
No hospitalizations related to PID were reported during the
prospective study period, and one patient reported hospitali-
zation due to PID-related pathologies (pneumonia) during the
retrospective period.
Treatment Satisfaction
At the 12-month follow-up visit, 76.5% of patients (n = 26)
were very satisfied and 23.5% (n = 8) of patients were quite
satisfied with biweekly Hizentra®. Only one patient, who
switched back to weekly administration of Hizentra® 22 days
after enrolment, remained unsatisfied, as reported at the 6-
monthly follow-up visit. Treatment with biweekly Hizentra®
was completed by 94% of patients (n = 33), while 5.7% of
patients (n = 2) switched back to the previous weekly regimen
(after 22 and 261 days, respectively). Reasons for the switch,
as reported by the treating physicians, were major discomfort
at the injection site (n = 1) and mottled cutaneous
thoracoabdominal vein reticulum (n = 1; anAE not considered
to be related to Hizentra®).
The patient who experienced major discomfort at the injec-
tion site was being treated with 12 g Hizentra® every 14 days,
administered using two pumps in parallel for three infusion
sites, with a cumulative rate of 32 mL/h. After 22 days with
biweekly Hizentra® treatment, therapy was switched to 6 g
Hizentra® every 7 days (no information is available on the
infusion parameters). The pain resolved when the patient was
switched back to weekly Hizentra® treatment.
Table 2 Pre-infusion IgG concentrations during biweekly Hizentra® dosing regimen
Pre-infusion IgG concentration (g/L) n Mean ± SD Median (IQR) 95% CI
12-month retrospective period 23 7.84 ± 2.09 8.03 (7.10–9.25) 6.94, 8.74
3-month follow-up 17 9.25 ± 1.99 8.57 (8.05–9.79) 8.23, 10.28
6-month follow-up 21 8.65 ± 1.94 8.15 (7.64–9.45) 7.77, 9.53
12-month follow-up 21 8.57 ± 1.99 7.98 (7.07–9.69) 7.66, 9.48
12-month prospective period 23 8.55 ± 1.76 7.94 (7.36–9.67) 7.79, 9.31
Intra-patient variation between prospective and retrospective periods 23 0.71 ± 2.81 0.10 (− 0.82–1.22) − 0.51, 1.92
CI confidence interval, IQR interquartile range, SD standard deviation
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The patient with mottled cutaneous thoracoabdominal vein
reticulumwas being treated with 8 g Hizentra® every 14 days,
administered using one pump for two infusion sites, with a
cumulative rate of 40 mL/h. After 261 days with biweekly
Hizentra® treatment, therapy was switched to 4 g Hizentra®
every 7 days, administered using one pump for two infusion
sites, with a cumulative rate of 40 mL/h. The mottled cutane-
ous thoracoabdominal vein reticulum disappeared on return to
weekly Hizentra® administration.
Safety Evaluation
During the prospective period, 22.9% of patients (n = 8) re-
ported 11 AEs, of which adverse drug reactions (ADRs) were
reported by two patients (edema at injection site) and serious
adverse events (SAEs) were reported in one patient (pneumo-
nia). The edema reported at the injection site by the two pa-
tients was mild and expected.
Discussion
This is the first prospective, multicenter, observational
study providing real-world evidence of the efficacy and
safety of biweekly Hizentra® in patients with PIDs. The
results of this study showed that biweekly administration
of Hizentra® maintained stable IgG concentrations in pa-
tients with PIDs that were comparable with weekly SCIG
administration. A study investigating the pharmacokinetics
and safety of biweekly 16% SCIG in patients with PAD
reported that the treatment was well tolerated with stable
serum IgG levels [24]. Other pharmacokinetic and retro-
spective studies have reported that biweekly 20% SCIG
therapy is well tolerated and results in stable serum IgG
levels [22, 25]. The results of the present study are consis-
tent with these observations and further show that despite a
slight reduction in the monthly dose of SCIG observed dur-
ing the prospective phase (median dose/infusion/2 weeks:
10 g) compared with the retrospective period with weekly
administration (median dose/infusion/week: 6 g), IgG se-
rum concentrations remained constant.
Regular monitoring of the patient’s serum IgG levels after
administration of a new therapy can help in measuring the
response to therapy. SCIG therapy is generally initiated at a
dose of 100–150 mg/kg/week, and the dose is subsequently
adjusted based on the serum IgG trough levels achieved for
individual patients [26–28]. It is recommended that during
treatment with IgG, the dose of IgG should be titrated to
achieve a serum trough level of about 6–8 g/L in patients
with PIDs to provide protection against infections [29, 30].
Pre-infusion serum IgG levels were monitored at regular
intervals during the present study and showed that biweekly
administration of Hizentra® maintained the pre-infusion
trough levels of IgG above 7.5 g/L throughout the prospec-
tive study period.
During the present study, no relevant changes in terms of
infections and hospitalizations were observed between the two
groups, and there was no increase in the number of days of
antibiotic therapy for infections in the prospective period com-
pared with the retrospective phase of the study. However, it
should be noted that the annual rate of infections (as well as
any other AEs) calculated for the retrospective period may
have been underestimated, as the data were collected retro-
spectively (recall bias). Also, other clinical findings errone-
ously reported as infections during the study may have been
related to inflammatory comorbidities frequently occurring in
patients with PIDs.
The mean annual rate of SBIs/patient during the prospec-
tive and retrospective period of the present study was identical
and comparable to previously published studies with
Hizentra® [13]. Moreover, rate of SBIs during the prospective
study period was well below the threshold (< 1 SBI) recom-
mended by the US FDA to show efficacy of IgG therapy [23].
Also, the percentage of patients with at least one other infec-
tion reported in the two phases of the present study was com-
parable with that reported in the phase III study (75 versus
Table 3 Other infections
(bacterial nail disorder, bronchitis,
cutaneous papule, diarrhea and
gastroenteritis, ear pain,
epididymitis, flu and cough,
genital candidiasis, herpes
labialis, influenza, lower rim
lesion, oral aphthae, oxyuriasis,
periocular herpes, scarlet fever,
streptococcus infection, tracheitis,
urinary tract infections,
vulvovaginitis) reported in
patients during the prospective
and retrospective study periods
Other infections Retrospective period, number of cases
(%)
Prospective period, number of cases
(%)
Total number of other
infections
40 (100) 62 (100)
Bronchitis 12 (30.0) 8 (12.7)
Rhinitis 4 (10.0) 5 (7.9)
Pharyngitis 8 (20.0) 14 (22.2)
Laryngitis 0 (0.0) 3 (4.8)
Otitis 1 (2.5) 1 (1.6)
Sinusitis 4 (10.0) 10 (15.9)
Conjunctivitis 1 (2.5) 0 (0.0)
Other type of infection 10 (25.0) 21 (33.9)
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78.3%) [13]. The choice of both retrospective and prospective
observation windows, accounting for 12 months each, was
intended to limit potential biases linked to the seasonal nature
of the incidence of infections.
Treatment with biweekly Hizentra® progressively showed
a high degree of patient satisfaction during this study. At the
12-month follow-up visit, all patients were at least quite satis-
fied, with the majority of patients being very satisfied (76.5%)
with the biweekly regimen, and 94% of patients chose to
continue the twice-monthly treatment protocol. Only one pa-
tient preferred to switch back to the weekly Hizentra® regi-
men because of discomfort experienced during the biweekly
administration due to increased volume of administration. It
has been documented that patients with PIDs may prefer a
regimen with more frequent infusions at a lower volume
[31]. With several options available for the administration of
IgG with different dosing frequencies, patients can select the
most suitable method based on individual preference [32].
Even though the study was not designed to monitor patient
quality of life, overall, these results suggest favorable effects
of the biweekly Hizentra® regimen.
In the present study, biweekly Hizentra®was well tolerated
in patients with PID. Two patients experienced edema at the
injection site (ADR) and one patient reported pneumonia
(SAE). However, these events did not interfere with the study
progression. Furthermore, it was observed that the SAE
(pneumonia) reported in one patient was not related to the
study medication, but was due to the primary immunodefi-
ciency itself. These AEs reported with SCIG administration
are less extensive than those caused by intravenous infusion
[14]. Edema at the injection site is an expected event consid-
ering the high volume of solutions injected subcutaneously,
which can be mitigated by dividing the dose to be adminis-
tered among several infusion sites [19].
The main limitation of the present study was the possible
introduction of bias for data collected retrospectively, espe-
cially due to missing or incomplete data. This was controlled
for by strictly allowing only patients with a minimum required
set of retrospective data available to be included in the study.
Also, the IBIS study did not determine patients’ quality of life.
In conclusion, the IBIS study highlights the benefits of a
biweekly Hizentra® treatment regimen in patients with PIDs
in a clinical setting. The study showed that switching from
weekly administration (or at any rate with a frequency of
every 0–10 days) of Hizentra® to once every 2 weeks
(biweekly) neither compromised serum IgG levels nor the rate
of infections and hospitalizations.
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